XML 38 R25.htm IDEA: XBRL DOCUMENT v3.26.3
Segment Information
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates as a single operating segment that is engaged in discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. A global research and development organization and a supply chain organization discover, develop, manufacture, and supply the Company’s products. A global commercial organization markets, distributes, and sells the products. The business is also supported by global corporate staff functions. The Company’s Chief Operating Decision Maker (the “CODM”) is the Chief Executive Officer, who assesses performance and allocates resources based on significant expenses and net income on a consolidated basis. The significant expenses that are regularly provided to the CODM include those amounts that are also reported on the consolidated statement of operations as well as below additional disaggregated measures. The CODM also reviews cash position (which includes cash and cash equivalents, current restricted cash, and short-term investments that are reported on the consolidated balance sheets) when making operating decisions. In accordance with ASC 280, the Company has only one reportable segment.
The following tables present disaggregated expenses that are regularly provided to the CODM:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Personnel compensation and related costs16,678 21,539 57,861 68,067 
Licensing fees— — 37,000 19,997 
CROs/CMOs/Investigators expenses and other costs33,132 26,389 82,306 71,207 
Total research and development expenses49,810 47,928 177,167 159,271 
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Clinical programs25,902 18,179 71,782 63,236 
Pre-Clinical programs3,296 1,982 34,621 10,365 
Unallocated research and development expenses20,612 27,767 70,764 85,670 
Total research and development expenses49,810 47,928 177,167 159,271 
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Personnel compensation and related costs39,210 41,320 124,978 124,642 
Other costs30,861 28,786 83,035 79,924 
Total selling, general, and administrative expenses70,071 70,106 208,013 204,566 
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Selling and marketing expenses51,425 47,179 146,419 135,882 
General and administrative expenses18,646 22,927 61,594 68,684 
Total selling, general, and administrative expenses70,071 70,106 208,013 204,566